Glenmark Pharmaceuticals schedules investor meetings in London

Glenmark Pharmaceuticals will conduct a series of analyst and institutional investor meetings in London from June 30 to July 1, 2026. The company has scheduled these physical sessions to engage with investors, comprising both group and one-on-one formats. No unpublished price sensitive information (UPSI) will be disclosed during the meetings, ensuring compliance with regulatory standards.

Meeting Details

The disclosure was made pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule is subject to change due to exigencies on the part of the investors or the company.

Date	Analyst/Institutional Investors/Event	Venue	Type of Meeting	Group / One-on-one
June 30, 2026 to July 01, 2026	Investor meetings	London	Physical	Both

Rashmi Khandelwal, Company Secretary & Compliance Officer at Glenmark Pharmaceuticals, signed the intimation on June 25, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.26%	+3.58%	+4.06%	+9.17%	+21.76%	+249.31%

Glenmark Pharmaceuticals Inc., USA announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the US market on June 17, 2026. The product is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, marketed by Provepharm SAS. This launch strengthens Glenmark's institutional portfolio in North America.

According to IQVIA sales data for the 12-month period ending April 2026, the market for ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), achieved annual sales of approximately $19.0 million. This figure includes sales of the brand and all available therapeutic equivalents. Glenmark's product is approved only for the indications listed in its approved label.

Market Context

The launch targets the institutional healthcare sector in the US. The following table outlines the key market metrics based on the provided data:

Metric:	Details
Reference Listed Drug:	ProvayBlue® Injection
Manufacturer of RLD:	Provepharm SAS
Market Sales (12 months ending April 2026):	$19.0 million
Glenmark Product Strength:	50 mg/10 mL (5 mg/mL)

Marc Kikuchi, President & Business Head, North America, stated that the launch reflects the company's commitment to expanding access to quality, affordable medicines for healthcare institutions and patients. He added that this addition reinforces the focus on delivering reliable treatment options across the US market.

Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with a presence in over 80 countries. The company operates 11 manufacturing facilities across four continents and six R&D centres.